Whole-genome sequencing of clarithromycin resistant Helicobacter pylori characterizes unidentified variants of multidrug resistant efflux pump genes

Gut Pathogens

Volumn 6, Issue 1, 2014, Pages

  Iwamoto, Akira ^a   Tanahashi, Toshihito ^a,b   Okada, Rina ^a   Yoshida, Yukio ^c   Kikuchi, Kaoru ^c   Keida, Yoshihide ^c   Murakami, Yoshiki ^d   Yang, Lin ^a   Yamamoto, Koji ^a   Nishiumi, Shin ^a   Yoshida, Masaru ^a   Azuma, Takeshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^c Okinawa Prefectural Chubu Hospital   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clarithromycin; Helicobacter pylori; Multidrug efflux; TolC homolog; Whole genome sequencing

Indexed keywords

EID: 84902899254     PISSN: None     EISSN: 17574749     Source Type: Journal    
DOI: 10.1186/1757-4749-6-27     Document Type: Article

References (43)

1. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Gisbert JP, Calvet X, Aliment Pharmacol Ther 2011 34 1255 1268
2. Clinical practice. Helicobacter pylori infection. McColl KE, N Engl J Med 2010 362 1597 1604
3. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ, Gut 2007 56 772 781 (Pubitemid 46854190)
4. [Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference]. Gisbert JP, Calvet X, Gomollon F, Mones J, Med Clin (Barc) 2005 125 301 316 (Pubitemid 41452252)
5. "Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, Sorrentino D, Gasbarrini G, Dig Liver Dis 2007 39 782 789 (Pubitemid 47046643)
6. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Chey WD, Wong BC, Am J Gastroenterol 2007 102 1808 1825 (Pubitemid 47206706)
7. Causes of failure of eradication of Helicobacter pylori. Jenks PJ, BMJ 2002 325 3 4 (Pubitemid 34747931)
8. Eradication therapy for Helicobacter pylori. Vakil N, Megraud F, Gastroenterology 2007 133 985 1001 (Pubitemid 47374146)
9. A report card to grade Helicobacter pylori therapy. Graham DY, Lu H, Yamaoka Y, Helicobacter 2007 12 275 278 (Pubitemid 47196342)
10. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF, Antimicrob Agents Chemother 1996 40 477 480 (Pubitemid 26049364)
11. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Taylor DE, Ge Z, Purych D, Lo T, Hiratsuka K, Antimicrob Agents Chemother 1997 41 2621 2628 (Pubitemid 27524731)
12. Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. Rimbara E, Noguchi N, Kawai T, Sasatsu M, Antimicrob Agents Chemother 2008 52 3465 3466
13. Gene mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pylori strains isolated from Korean patients. Kim JM, Kim JS, Kim N, Kim YJ, Kim IY, Chee YJ, Lee CH, Jung HC, J Microbiol Biotechnol 2008 18 1584 1589
14. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Nash KA, Brown-Elliott BA, Wallace RJ Jr, Antimicrob Agents Chemother 2009 53 1367 1376
15. Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. Roberts M, FEMS Microbiol Lett 2008 282 147 159 (Pubitemid 351569469)
16. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. Hirata K, Suzuki H, Nishizawa T, Tsugawa H, Muraoka H, Saito Y, Matsuzaki J, Hibi T, J Gastroenterol Hepatol 2010 25 Suppl 1 75 S79
17. Claritromycin resistance and Helicobacter pylori genotypes in Italy. De Francesco V, Margiotta M, Zullo A, Hassan C, Valle ND, Burattini O, D'Angelo R, Stoppino G, Cea U, Giorgio F, Monno R, Morini S, Panella C, Ierardi E, J Microbiol 2006 44 660 664 (Pubitemid 46409796)
18. Analysis of clarithromycin resistance and CagA status in Helicobacter pylori by use of feces from children in Thailand. Tanuma M, Rimbara E, Noguchi N, Boonyaritichaikij S, Kuwabara K, Fukunaga Y, Sasatsu M, J Clin Microbiol 2009 47 4144 4145
19. Application of 'next-generation' sequencing technologies to microbial genetics. MacLean D, Jones JD, Studholme DJ, Nat Rev Microbiol 2009 7 287 296
20. Transforming clinical microbiology with bacterial genome sequencing. Didelot X, Bowden R, Wilson DJ, Peto TE, Crook DW, Nat Rev Genet 2012 13 601 612
21. High-throughput bacterial genome sequencing: an embarrassment of choice, a world of opportunity. Loman NJ, Constantinidou C, Chan JZ, Halachev M, Sergeant M, Penn CW, Robinson ER, Pallen MJ, Nat Rev Microbiol 2012 10 599 606
22. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. Koser CU, Ellington MJ, Cartwright EJ, Gillespie SH, Brown NM, Farrington M, Holden MT, Dougan G, Bentley SD, Parkhill J, Peacock SJ, PLoS Pathog 2012 8 1002824
23. A Helicobacter pylori TolC efflux pump confers resistance to metronidazole. van Amsterdam K, Bart A, van der Ende A, Antimicrob Agents Chemother 2005 49 1477 1482 (Pubitemid 40463379)
24. Accurate whole human genome sequencing using reversible terminator chemistry. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM, Bryant J, Carter RJ, Keira Cheetham R, Cox AJ, Ellis DJ, Flatbush MR, Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li H, Liu X, Maisinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML, Pratt MR, et al. Nature 2008 456 53 59
25. Performance comparison of exome DNA sequencing technologies. Clark MJ, Chen R, Lam HY, Karczewski KJ, Chen R, Euskirchen G, Butte AJ, Snyder M, Nat Biotechnol 2011 29 908 914
26. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, Bell J, Coombs G, Bennett-Wood V, Porter JL, Robins-Browne R, Davies JK, Seemann T, Stinear TP, PLoS Pathog 2011 7 1002359
27. Choosing a benchtop sequencing machine to characterise Helicobacter pylori genomes. Perkins TT, Tay CY, Thirriot F, Marshall B, PLoS One 2013 8 67539
28. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, Bertoni A, Swerdlow HP, Gu Y, BMC Genomics 2012 13 341
29. Detecting genomic indel variants with exact breakpoints in single- and paired-end sequencing data using SplazerS. Emde AK, Schulz MH, Weese D, Sun R, Vingron M, Kalscheuer VM, Haas SA, Reinert K, Bioinformatics 2012 28 619 627
30. Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR. Nishizawa T, Suzuki H, Umezawa A, Muraoka H, Iwasaki E, Masaoka T, Kobayashi I, Hibi T, J Clin Microbiol 2007 45 303 305
31. Determination of mutations of the 23S rRNA gene of Helicobacter pylori by allele specific primer-polymerase chain reaction method. Nakamura A, Furuta T, Shirai N, Sugimoto M, Kajimura M, Soya Y, Hishida A, J Gastroenterol Hepatol 2007 22 1057 1063 (Pubitemid 47019849)
32. Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. Furuta T, Soya Y, Sugimoto M, Shirai N, Nakamura A, Kodaira C, Nishino M, Okuda M, Okimoto T, Murakami K, Fujioka T, Hishida A, J Gastroenterol Hepatol 2007 22 1810 1815 (Pubitemid 47525091)
33. Adaptive evolution of Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patient. McAdam PR, Holmes A, Templeton KE, Fitzgerald JR, PLoS One 2011 6 24301
34. Evidence for several waves of global transmission in the seventh cholera pandemic. Mutreja A, Kim DW, Thomson NR, Connor TR, Lee JH, Kariuki S, Croucher NJ, Choi SY, Harris SR, Lebens M, Niyogi SK, Kim EJ, Ramamurthy T, Chun J, Wood JL, Clemens JD, Czerkinsky C, Nair GB, Holmgren J, Parkhill J, Dougan G, Nature 2011 477 462 465
35. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. Okusu H, Ma D, Nikaido H, J Bacteriol 1996 178 306 308 (Pubitemid 26006095)
36. Crystal structure of bacterial multidrug efflux transporter AcrB. Murakami S, Nakashima R, Yamashita E, Yamaguchi A, Nature 2002 419 587 593
37. Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nakashima R, Sakurai K, Yamasaki S, Nishino K, Yamaguchi A, Nature 2011 480 565 569
38. Alignment and structure prediction of divergent protein families: periplasmic and outer membrane proteins of bacterial efflux pumps. Johnson JM, Church GM, J Mol Biol 1999 287 695 715 (Pubitemid 29168442)
39. Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Bina JE, Alm RA, Uria-Nickelsen M, Thomas SR, Trust TJ, Hancock RE, Antimicrob Agents Chemother 2000 44 248 254 (Pubitemid 30060714)
40. RND multidrug efflux pumps: what are they good for? Alvarez-Ortega C, Olivares J, Martinez JL, Front Microbiol 2013 4 7
41. Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helicobacter pylori. Tsugawa H, Suzuki H, Muraoka H, Ikeda F, Hirata K, Matsuzaki J, Saito Y, Hibi T, Biochem Biophys Res Commun 2011 404 656 660
42. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. Binh TT, Shiota S, Suzuki R, Matsuda M, Trang TT, Kwon DH, Iwatani S, Yamaoka Y, J Antimicrob Chemother 2014 [Epub ahead of print]
43. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. Clinical and Laboratory Standards Institute, CLSI PA, USA: Wayne 2007